Estrogen receptor-β as a potential target for colon cancer prevention: Chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats

Cancer Prevention Research

Volumn 2, Issue 1, 2009, Pages 52-59

  Janakiram, Naveena B ^a   Steele, Vernon E ^b   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Chemopreventive Agent Development Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; ESTROGEN RECEPTOR BETA; MESSENGER RNA; RALOXIFENE; ANTINEOPLASTIC AGENT; CARCINOGEN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHROMOSOME ABERRATION; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; DRUG DOSE COMPARISON; FISCHER 344 RAT; GENE LOCUS; HUMAN; HUMAN CELL; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UPREGULATION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; AZOXYMETHANE; BLOTTING, WESTERN; CARCINOGENS; CELL LINE, TUMOR; CHEMOPREVENTION; COLONIC NEOPLASMS; ESTROGEN RECEPTOR BETA; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MAXIMUM TOLERATED DOSE; RALOXIFENE; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 62349098202     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0140     Document Type: Article

References (45)

1. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-346
2. Segars JH, Driggers PH. Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol Metab 2002;13:349-354
3. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-645
4. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene in postmenopausal women. JAMA 1999;281:2189-2197
5. Katznellenbogen BS, Katznellenbogen JA. Defining the "S" in SERMs. Science 2002;295:2380-2381
6. Kuiper GGJM, Lemmen JG, Carisson B. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor-β. Endocrinology 1998;3:4252-4263
7. Lonard DM, Smith CL. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroid 2002;67:15-24.
8. Bryant HU, Glasebrook AL, Yang NN, Sato M. An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 1999;69:37-44. (Pubitemid 29305524)
9. Enmark E, Pelto-Huikko M, Randien K. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82:4258-4265 (Pubitemid 27525550)
10. Bryant HU, Wilson PK, Adrian MD. Selective estrogen receptor modulators: pharmacological profile in the rat uterus. J Soc Gynecol Investig 1996;3:152A.
11. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-2468
12. Chen MJ, Longnecker MP, Morgenstern H, Lee ER, Frankl HD, Haile RW. Recent use of hormone replacement therapy and the prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1998;7:227-230 (Pubitemid 28353933)
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333
14. Ries LAG, Eisner MP, Kosary CL. SEER cancer statistics review. Bethesda (MD): National Cancer Institute; 2003. p. 1975-2001.
15. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
16. Naveena BJ, Indranie C, Altaf M, Steele VE, Rao CV. β-Ionone inhibits colonic aberrant crypt foci in rats, suppresses cell growth and induces retinoid X receptor α in human colon cancer cells. Mol Cancer Ther 2008;7:181-190
17. Vogel VG, Costantino JP, Wickerham DL. Effect of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741
18. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002;62:1370-1376 (Pubitemid 34407794)
19. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 1999;20:253-278
20. Xu X, Thomas ML. Estrogen receptor-mediated direct simulation of colon cancer cell growth in vitro. Mol Cell Endocrinol 1994;105:197-201. (Pubitemid 24313988)
21. Wong NACS, Malcomson RDG, Jodrell ID, et al. ER-β isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 2005;207:53-60.
22. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ER-β isoforms in colon cancer. Cancer Res 2001;61:632-640 (Pubitemid 32128626)
23. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor β in colon cancer cell lines. Biophys Res Commun 1999;261:521-527 (Pubitemid 29392509)
24. Jensen EV, Cheng G, Palmieri C, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 2001;4:4. (Pubitemid 34019150)
25. Krista AP, Thompson LU. Ligand-induced regulation of ERα and ERβ is indicative of human breast cancer cell proliferation. Breast Cancer Res Treat 2003;81:209-221 (Pubitemid 37352458)
26. Rao CV, Wang C-X, Simi B, et al. Enhancement of experimental colon cancer by genistein. Cancer Res 1997;57:3717-3722 (Pubitemid 27381214)
27. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999;59:5421-5424 (Pubitemid 29526448)
28. Konstantinopoulos PA, Kominea AV, Oros G, et al. Oestrogen receptor β (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003;39:1251-1258
29. Witte D, Chirala M, Younes A, Li Y, Younes M. Estrogen receptor β is expressed in human colorectal adenocarcinoma. Hum Pathol 2001;32:940-944 (Pubitemid 32911316)
30. Wada-Hiraike O, Imamov O, Hiraike H, et al. Role of estrogen receptor β in colonic epithelium. Proc Natl Acad Sci U S A 2006;103:2959-2964 (Pubitemid 43308324)
31. Min/+ mice. Int J Cancer 2008;123:303-311 (Pubitemid 351842014)
32. Cho NL, Javid SH, Carothers AM, Redston M, Beragnolli MM. Estrogen receptors α and β are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 2007;67:2366-2372 (Pubitemid 46437055)
33. Rao CV, Desai D, Simi B, Kulkarni N, et al. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res 1993;53:4182-4188 (Pubitemid 24146764)
34. Rao CV, Simi B, Reddy BS. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993;14:2219-2225 (Pubitemid 23335173)
35. Rao CV, Yoshinobu H, Cooma I, Reddy BS. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61:1927-1933
36. Wakeling AE, Valcaccia B. Antiestrogenic and antitumor activities of a series of non-steroidal anti-estrogens. J Endocrinol 1983;99:455-464
37. Yi KI, Kim B-C, Seong Do H, et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 2002;62:5365-5369
38. Mclellan EA, Bird RP. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 1988;48:6187-6192
39. Mclellan E, Medline A, Bird RP. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci-putative preneoplastic lesions. Cancer Res 1991;51:5270-5274
40. Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA. Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J Cell Biochem 1992; 166:55-62.
41. Wargovich MJ, Chen CD, Jimenez A, et al. Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 1996;5:355-360 (Pubitemid 26139118)
42. Chambliss KL, Yuhanna IS, Anderson RGW, et al. ER-β has nongenomic action in caveolae. Mol Endocrinol 2002;16:938-946
43. Patlolla JM, Swamy MV, Raju J, Rao CV. Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncol Rep 2004;11:957-963
44. Emanuela E, Anna I, Giuseppina MR, et al. Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. Endocrinology 2005;146:3301-3308
45. Dowsett M, Bundred NJ, Decensi A, et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis. Cancer Epidemiol Biomarkers Prev 2001;10:961-966